The safety of Sonovue® in abdominal applications: Retrospective analysis of 23188 investigations

Fabio Piscaglia, Luigi Bolondi, L. Aiani, M. Luigi Angeli, V. Arienti, L. Barozzi, R. Basilico, M. Bertolotto, E. Biasini, P. Busilacchi, F. Calliada, M. Caremani, E. Caturelli, N. Celli, A. Colecchia, L. Cova, M. Assunta Cova, L. Crocetti, I. de Sio, F. DrudiG. Ferraioli, C. Filice, F. Fornari, S. Gaiani, F. Giangregorio, A. Giorgio, T. Ierace, Riccardo Lencioni, T. Livraghi, F. Magnolfi, A. Martegani, F. Meloni, G. Menozzi, G. Pelosi, M. Pompili, L. Riccardi, P. Ricci, L. Rubaltelli, D. Sacerdoti, G. Serafini, C. Serra, L. Solbiati, D. Tacconi, M. Valentino, G. Vidili, F. Vitali

Research output: Contribution to journalArticle

394 Citations (Scopus)

Abstract

The aim of the present retrospective study was to assess the incidence of adverse events (AE) of a second-generation ultrasound contrast agent in real clinical practice. A total of 28 Italian Centres provided data on the postmarketing use of SonoVue® (Bracco Spa, Milan, Italy) in abdominal examination performed between December 2001 and December 2004. A total of 23 188 investigations were reported. No fatal event occurred. AEs were reported in 29 cases, of which only two were graded as serious; the rest, 27, were nonserious (23 mild, three moderate and one severe). The overall reporting rate of serious AE was 0.0086%. Overall, only four AEs required treatment (two serious, two nonserious including one moderate and one severe AEs). In conclusion, the present large-scale retrospective analysis showed that SonoVue has a good safety profile in abdominal applications, with an AE reporting rate lower than or similar to that reported for radiologic and magnetic resonance contrast agents. (E-mail: Piscagl@med.unibo.it).

Original languageEnglish (US)
Pages (from-to)1369-1375
Number of pages7
JournalUltrasound in Medicine and Biology
Volume32
Issue number9
DOIs
StatePublished - Sep 2006
Externally publishedYes

Fingerprint

Contrast Media
safety
Safety
Italy
Magnetic Resonance Spectroscopy
Retrospective Studies
Incidence
magnetic resonance
incidence
examination
contrast agent BR1
profiles

Keywords

  • Adverse effect
  • Contrast agents
  • Contrast-enhanced ultrasonography
  • Ultrasound

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Piscaglia, F., Bolondi, L., Aiani, L., Luigi Angeli, M., Arienti, V., Barozzi, L., ... Vitali, F. (2006). The safety of Sonovue® in abdominal applications: Retrospective analysis of 23188 investigations. Ultrasound in Medicine and Biology, 32(9), 1369-1375. https://doi.org/10.1016/j.ultrasmedbio.2006.05.031

The safety of Sonovue® in abdominal applications : Retrospective analysis of 23188 investigations. / Piscaglia, Fabio; Bolondi, Luigi; Aiani, L.; Luigi Angeli, M.; Arienti, V.; Barozzi, L.; Basilico, R.; Bertolotto, M.; Biasini, E.; Busilacchi, P.; Calliada, F.; Caremani, M.; Caturelli, E.; Celli, N.; Colecchia, A.; Cova, L.; Assunta Cova, M.; Crocetti, L.; de Sio, I.; Drudi, F.; Ferraioli, G.; Filice, C.; Fornari, F.; Gaiani, S.; Giangregorio, F.; Giorgio, A.; Ierace, T.; Lencioni, Riccardo; Livraghi, T.; Magnolfi, F.; Martegani, A.; Meloni, F.; Menozzi, G.; Pelosi, G.; Pompili, M.; Riccardi, L.; Ricci, P.; Rubaltelli, L.; Sacerdoti, D.; Serafini, G.; Serra, C.; Solbiati, L.; Tacconi, D.; Valentino, M.; Vidili, G.; Vitali, F.

In: Ultrasound in Medicine and Biology, Vol. 32, No. 9, 09.2006, p. 1369-1375.

Research output: Contribution to journalArticle

Piscaglia, F, Bolondi, L, Aiani, L, Luigi Angeli, M, Arienti, V, Barozzi, L, Basilico, R, Bertolotto, M, Biasini, E, Busilacchi, P, Calliada, F, Caremani, M, Caturelli, E, Celli, N, Colecchia, A, Cova, L, Assunta Cova, M, Crocetti, L, de Sio, I, Drudi, F, Ferraioli, G, Filice, C, Fornari, F, Gaiani, S, Giangregorio, F, Giorgio, A, Ierace, T, Lencioni, R, Livraghi, T, Magnolfi, F, Martegani, A, Meloni, F, Menozzi, G, Pelosi, G, Pompili, M, Riccardi, L, Ricci, P, Rubaltelli, L, Sacerdoti, D, Serafini, G, Serra, C, Solbiati, L, Tacconi, D, Valentino, M, Vidili, G & Vitali, F 2006, 'The safety of Sonovue® in abdominal applications: Retrospective analysis of 23188 investigations', Ultrasound in Medicine and Biology, vol. 32, no. 9, pp. 1369-1375. https://doi.org/10.1016/j.ultrasmedbio.2006.05.031
Piscaglia, Fabio ; Bolondi, Luigi ; Aiani, L. ; Luigi Angeli, M. ; Arienti, V. ; Barozzi, L. ; Basilico, R. ; Bertolotto, M. ; Biasini, E. ; Busilacchi, P. ; Calliada, F. ; Caremani, M. ; Caturelli, E. ; Celli, N. ; Colecchia, A. ; Cova, L. ; Assunta Cova, M. ; Crocetti, L. ; de Sio, I. ; Drudi, F. ; Ferraioli, G. ; Filice, C. ; Fornari, F. ; Gaiani, S. ; Giangregorio, F. ; Giorgio, A. ; Ierace, T. ; Lencioni, Riccardo ; Livraghi, T. ; Magnolfi, F. ; Martegani, A. ; Meloni, F. ; Menozzi, G. ; Pelosi, G. ; Pompili, M. ; Riccardi, L. ; Ricci, P. ; Rubaltelli, L. ; Sacerdoti, D. ; Serafini, G. ; Serra, C. ; Solbiati, L. ; Tacconi, D. ; Valentino, M. ; Vidili, G. ; Vitali, F. / The safety of Sonovue® in abdominal applications : Retrospective analysis of 23188 investigations. In: Ultrasound in Medicine and Biology. 2006 ; Vol. 32, No. 9. pp. 1369-1375.
@article{803f36c2a8064cc2af59c22f185ea4d0,
title = "The safety of Sonovue{\circledR} in abdominal applications: Retrospective analysis of 23188 investigations",
abstract = "The aim of the present retrospective study was to assess the incidence of adverse events (AE) of a second-generation ultrasound contrast agent in real clinical practice. A total of 28 Italian Centres provided data on the postmarketing use of SonoVue{\circledR} (Bracco Spa, Milan, Italy) in abdominal examination performed between December 2001 and December 2004. A total of 23 188 investigations were reported. No fatal event occurred. AEs were reported in 29 cases, of which only two were graded as serious; the rest, 27, were nonserious (23 mild, three moderate and one severe). The overall reporting rate of serious AE was 0.0086{\%}. Overall, only four AEs required treatment (two serious, two nonserious including one moderate and one severe AEs). In conclusion, the present large-scale retrospective analysis showed that SonoVue has a good safety profile in abdominal applications, with an AE reporting rate lower than or similar to that reported for radiologic and magnetic resonance contrast agents. (E-mail: Piscagl@med.unibo.it).",
keywords = "Adverse effect, Contrast agents, Contrast-enhanced ultrasonography, Ultrasound",
author = "Fabio Piscaglia and Luigi Bolondi and L. Aiani and {Luigi Angeli}, M. and V. Arienti and L. Barozzi and R. Basilico and M. Bertolotto and E. Biasini and P. Busilacchi and F. Calliada and M. Caremani and E. Caturelli and N. Celli and A. Colecchia and L. Cova and {Assunta Cova}, M. and L. Crocetti and {de Sio}, I. and F. Drudi and G. Ferraioli and C. Filice and F. Fornari and S. Gaiani and F. Giangregorio and A. Giorgio and T. Ierace and Riccardo Lencioni and T. Livraghi and F. Magnolfi and A. Martegani and F. Meloni and G. Menozzi and G. Pelosi and M. Pompili and L. Riccardi and P. Ricci and L. Rubaltelli and D. Sacerdoti and G. Serafini and C. Serra and L. Solbiati and D. Tacconi and M. Valentino and G. Vidili and F. Vitali",
year = "2006",
month = "9",
doi = "10.1016/j.ultrasmedbio.2006.05.031",
language = "English (US)",
volume = "32",
pages = "1369--1375",
journal = "Ultrasound in Medicine and Biology",
issn = "0301-5629",
publisher = "Elsevier USA",
number = "9",

}

TY - JOUR

T1 - The safety of Sonovue® in abdominal applications

T2 - Retrospective analysis of 23188 investigations

AU - Piscaglia, Fabio

AU - Bolondi, Luigi

AU - Aiani, L.

AU - Luigi Angeli, M.

AU - Arienti, V.

AU - Barozzi, L.

AU - Basilico, R.

AU - Bertolotto, M.

AU - Biasini, E.

AU - Busilacchi, P.

AU - Calliada, F.

AU - Caremani, M.

AU - Caturelli, E.

AU - Celli, N.

AU - Colecchia, A.

AU - Cova, L.

AU - Assunta Cova, M.

AU - Crocetti, L.

AU - de Sio, I.

AU - Drudi, F.

AU - Ferraioli, G.

AU - Filice, C.

AU - Fornari, F.

AU - Gaiani, S.

AU - Giangregorio, F.

AU - Giorgio, A.

AU - Ierace, T.

AU - Lencioni, Riccardo

AU - Livraghi, T.

AU - Magnolfi, F.

AU - Martegani, A.

AU - Meloni, F.

AU - Menozzi, G.

AU - Pelosi, G.

AU - Pompili, M.

AU - Riccardi, L.

AU - Ricci, P.

AU - Rubaltelli, L.

AU - Sacerdoti, D.

AU - Serafini, G.

AU - Serra, C.

AU - Solbiati, L.

AU - Tacconi, D.

AU - Valentino, M.

AU - Vidili, G.

AU - Vitali, F.

PY - 2006/9

Y1 - 2006/9

N2 - The aim of the present retrospective study was to assess the incidence of adverse events (AE) of a second-generation ultrasound contrast agent in real clinical practice. A total of 28 Italian Centres provided data on the postmarketing use of SonoVue® (Bracco Spa, Milan, Italy) in abdominal examination performed between December 2001 and December 2004. A total of 23 188 investigations were reported. No fatal event occurred. AEs were reported in 29 cases, of which only two were graded as serious; the rest, 27, were nonserious (23 mild, three moderate and one severe). The overall reporting rate of serious AE was 0.0086%. Overall, only four AEs required treatment (two serious, two nonserious including one moderate and one severe AEs). In conclusion, the present large-scale retrospective analysis showed that SonoVue has a good safety profile in abdominal applications, with an AE reporting rate lower than or similar to that reported for radiologic and magnetic resonance contrast agents. (E-mail: Piscagl@med.unibo.it).

AB - The aim of the present retrospective study was to assess the incidence of adverse events (AE) of a second-generation ultrasound contrast agent in real clinical practice. A total of 28 Italian Centres provided data on the postmarketing use of SonoVue® (Bracco Spa, Milan, Italy) in abdominal examination performed between December 2001 and December 2004. A total of 23 188 investigations were reported. No fatal event occurred. AEs were reported in 29 cases, of which only two were graded as serious; the rest, 27, were nonserious (23 mild, three moderate and one severe). The overall reporting rate of serious AE was 0.0086%. Overall, only four AEs required treatment (two serious, two nonserious including one moderate and one severe AEs). In conclusion, the present large-scale retrospective analysis showed that SonoVue has a good safety profile in abdominal applications, with an AE reporting rate lower than or similar to that reported for radiologic and magnetic resonance contrast agents. (E-mail: Piscagl@med.unibo.it).

KW - Adverse effect

KW - Contrast agents

KW - Contrast-enhanced ultrasonography

KW - Ultrasound

UR - http://www.scopus.com/inward/record.url?scp=33748316416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748316416&partnerID=8YFLogxK

U2 - 10.1016/j.ultrasmedbio.2006.05.031

DO - 10.1016/j.ultrasmedbio.2006.05.031

M3 - Article

C2 - 16965977

AN - SCOPUS:33748316416

VL - 32

SP - 1369

EP - 1375

JO - Ultrasound in Medicine and Biology

JF - Ultrasound in Medicine and Biology

SN - 0301-5629

IS - 9

ER -